Raub Brock Capital Management LP Decreased By $669,118 Its Amgen (AMGN) Stake; Henry Schein (HSIC) Sentiment Is 0.81

June 19, 2017 - By Ellis Scott

Raub Brock Capital Management Lp decreased Amgen Inc. (AMGN) stake by 6.06% reported in 2016Q4 SEC filing. Raub Brock Capital Management Lp sold 4,583 shares as Amgen Inc. (AMGN)’s stock declined 9.68%. The Raub Brock Capital Management Lp holds 71,034 shares with $10.39M value, down from 75,617 last quarter. Amgen Inc. now has $118.21 billion valuation. The stock decreased 1.03% or $1.69 on June 16, reaching $162.42. About shares traded. Amgen, Inc. (NASDAQ:AMGN) has risen 5.27% since June 19, 2016 and is uptrending. It has underperformed by 11.43% the S&P500.

Henry Schein, Inc. is a provider of healthcare services and products primarily to office dental, animal health and medical practitioners. The company has market cap of $14.42 billion. The Firm operates through two divisions: healthcare distribution, and technology and value-added services. It has a 27.76 P/E ratio. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Ratings analysis reveals 67% of Henry Schein’s analysts are positive. Out of 6 Wall Street analysts rating Henry Schein, 4 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $164.0 while the high is $208.0. The stock’s average target of $189.33 is 3.61% above today’s ($182.73) share price. HSIC was included in 6 notes of analysts from September 12, 2016. On Wednesday, February 22 the stock rating was maintained by Barrington Research with “Outperform”. The stock has “Neutral” rating by Northcoast on Tuesday, December 6. Goldman Sachs upgraded Henry Schein, Inc. (NASDAQ:HSIC) on Tuesday, October 11 to “Buy” rating. The rating was initiated by Bank of America on Monday, September 12 with “Buy”. The stock has “Neutral” rating by Robert W. Baird on Friday, October 14. The rating was upgraded by Gabelli to “Buy” on Tuesday, January 10.

Since January 1, 0001, it had 0 insider buys, and 17 insider sales for $18.90 million activity.

Alecta Pensionsforsakring Omsesidigt holds 3.51% of its portfolio in Henry Schein, Inc. for 2.51 million shares. North Point Portfolio Managers Corp Oh owns 110,309 shares or 3.16% of their US portfolio. Moreover, Tirschwell & Loewy Inc has 2.65% invested in the company for 97,544 shares. The Delaware-based Green Valley Investors Llc has invested 2.47% in the stock. Mountain Pacific Investment Advisers Inc Id, a Idaho-based fund reported 143,008 shares.

The stock decreased 0.51% or $0.93 on June 16, reaching $182.73. About shares traded. Henry Schein, Inc. (HSIC) has risen 4.05% since June 19, 2016 and is uptrending. It has underperformed by 12.65% the S&P500.

Since May 24, 2017, it had 0 insider purchases, and 2 insider sales for $1.02 million activity. Shares for $451,164 were sold by Patton Cynthia M. BALTIMORE DAVID sold $569,541 worth of stock or 3,700 shares.

Investors sentiment decreased to 1.09 in Q4 2016. Its down 0.17, from 1.26 in 2016Q3. It dropped, as 98 investors sold AMGN shares while 488 reduced holdings. 111 funds opened positions while 527 raised stakes. 561.98 million shares or 1.23% less from 568.98 million shares in 2016Q3 were reported. Covington Capital Mngmt has invested 0.59% in Amgen, Inc. (NASDAQ:AMGN). Payden And Rygel reported 83,850 shares. Samlyn Ltd Llc reported 458,000 shares. Cap City Tru Fl has 0.25% invested in Amgen, Inc. (NASDAQ:AMGN). Ferguson Wellman Capital Management has invested 1.14% in Amgen, Inc. (NASDAQ:AMGN). Robeco Institutional Asset Management Bv invested 0.49% in Amgen, Inc. (NASDAQ:AMGN). Check Ca holds 0.04% or 3,558 shares. Fulton Breakefield Broenniman Ltd Liability Company has invested 1.13% in Amgen, Inc. (NASDAQ:AMGN). Holderness Invests Company holds 0.67% or 5,151 shares. Nadler Fin Gp Incorporated Inc stated it has 0.12% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Ally Fincl has 18,000 shares. Badgley Phelps & Bell holds 0.7% or 55,040 shares. Putnam Fl Investment Mgmt accumulated 2,397 shares. Wellington Shields Limited holds 2,375 shares or 0.06% of its portfolio. Guardian Investment Mgmt reported 16,241 shares.

Among 19 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 have Buy rating, 0 Sell and 9 Hold. Therefore 53% are positive. Amgen Inc. had 34 analyst reports since August 3, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $18900 target in Monday, June 5 report. The firm earned “Hold” rating on Friday, August 26 by Gabelli. Oppenheimer initiated the stock with “Outperform” rating in Tuesday, December 13 report. The company was maintained on Thursday, October 29 by UBS. Vetr upgraded the shares of AMGN in report on Friday, August 21 to “Buy” rating. Morgan Stanley upgraded the stock to “Overweight” rating in Tuesday, December 15 report. The rating was initiated by Leerink Swann on Friday, February 5 with “Market Perform”. The company was maintained on Friday, July 31 by RBC Capital Markets. The stock has “Overweight” rating by Piper Jaffray on Thursday, November 5. The rating was initiated by Atlantic Securities on Friday, December 18 with “Overweight”.

Analysts await Amgen, Inc. (NASDAQ:AMGN) to report earnings on July, 26. They expect $3.09 earnings per share, up 8.80% or $0.25 from last year’s $2.84 per share. AMGN’s profit will be $2.25B for 13.14 P/E if the $3.09 EPS becomes a reality. After $3.15 actual earnings per share reported by Amgen, Inc. for the previous quarter, Wall Street now forecasts -1.90% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: